Kyoto University · Medicine
Professor Yuki Muraoka's research lab specializes in retinal and choroidal imaging using advanced optical coherence tomography (OCT) techniques, with a focus on understanding the morphological and functional changes in retinal vascular diseases and degenerative conditions. The lab investigates pathological mechanisms in conditions such as central serous chorioretinopathy (CSC), branch retinal vein occlusion (BRVO), and retinal vascular tortuosity, emphasizing the role of structural changes in the retina and choroid. A key direction involves correlating OCT findings with visual outcomes to improve diagnosis and treatment strategies, particularly in macular edema and hemorrhagic complications. The lab also contributes to refining terminology and classification of retinal lesions, such as paravascular inner retinal defects (PIRD), for more precise clinical interpretation.
Figures are computed from collected data and may differ slightly.
Enhanced depth imaging of SS-OCT facilitated the analysis of WF changes in choroidal thickness in both healthy patients and patients with CSC. The local factors of the affected vortex vein and systemic risk factors may be involved in the pathogenesis of CSC.
Paravascular inner retinal defects primarily occur in eyes with high myopia or epiretinal membrane. Deviated retinal vessels due to axial elongation or epiretinal membrane traction may be involved in the pathogenesis. Paravascular inner retinal defects often cause retinal dysfunction corresponding to the location. A PIRD may partially overlap with retinal lesions previously reported as cleavage of the retinal nerve fiber layer, inner retinal cleavage, paravascular retinal cysts, or lamellar hole
In eyes with CRVO, OCT can be used to visualize anteroposterior venous tortuosity and associated structural changes to the retinal parenchyma.
To investigate the functional and morphologic prognoses of eyes with subfoveal hemorrhage from acute branch retinal vein occlusion (BRVO), and to examine the effect of intravitreal ranibizumab injection (IVR) on these prognoses, we assessed 81 eyes with acute BRVO, of which 38 did not receive IVR [IVR(-) group], and 43 were treated with IVR [IVR(+) group] for macular edema. The foveal morphologic changes were examined via optical coherence tomography (OCT). At initial examination, 63 eyes exhibi
Open papers in the app to read, cite, and organize with AI.
